Overview
Fyza Shaikh is an Assistant Professor in Cancer Immunology in the Department of Oncology in the Sidney Kimmel Comprehensive Cancer Center. She joined the faculty after completing her fellowship in medical oncology at Johns Hopkins School of Medicine (JHSOM) and residency in internal medicine at the University of Pittsburgh Medical Center as part of the ABIM research pathway. She received her MD and PhD in Microbiology and Immunology at Vanderbilt University School of Medicine. The Shaikh lab at JHSOM is focused on how the microbiome impacts host immunological responses to tumorigenesis and anti-tumor responses to immunomodulatory agents. The lab uses a combination of translational approaches using samples collected from human cohort studies and clinical trials as well as murine models to ask more detailed mechanistic questions and works across multiple tumor types (melanoma, lung, esophageal, head and neck, etc). The overall approach uses combination of clinical, computational, and lab-based techniques using a rich biorepository containing clinically annotated metadata with known and putative biomarkers of ICI response, such as PD-L1 and tumor mutational burden, paired with longitudinal fecal and plasma samples that correlate with clinical milestones (i.e. response/nonresponse by imaging and treatment-related toxicity). The goal is to focus on microbial functionality and build defined bacterial consortia that can then be tested in murine models to define colonization, metabolomics, and intra-tumoral immune response. This translational approach, with cross-sectional and longitudinal analysis of human samples, paired with mechanistic studies in murine models, has the potential to address both limitations in previously published studies and generate new hypotheses to make advances in this field and improve ICI responses for patients with advanced malignancies.
Dr. Shaikh is rated as an Experienced provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Esophageal Cancer.
Her clinical research consists of co-authoring 17 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Squamous Cell Skin Carcinoma.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
Locations
Baltimore, MD 21287
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Skip Viragh Outpatient Cancer Center
Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Pancreaticoduodenectomy.
Inova Health Care Services
Sekwon Jang is a Hematologist Oncology specialist and an Oncologist in Falls Church, Virginia. Dr. Jang is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma (CTCL), and Squamous Cell Skin Carcinoma. Dr. Jang is currently accepting new patients.
University Of Maryland Oncology Associates PA
Ranee Mehra is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Mehra is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Tongue Cancer, and Glossectomy. Dr. Mehra is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Esophageal CancerDr. Shaikh isExperienced. Learn about Esophageal Cancer.
- Gallbladder AdenocarcinomaDr. Shaikh isExperienced. Learn about Gallbladder Adenocarcinoma.
- Gallbladder CancerDr. Shaikh isExperienced. Learn about Gallbladder Cancer.
- Lung CancerDr. Shaikh isExperienced. Learn about Lung Cancer.
- MelanomaDr. Shaikh isExperienced. Learn about Melanoma.
- Non-Small Cell Lung Cancer (NSCLC)Dr. Shaikh isExperienced. Learn about Non-Small Cell Lung Cancer (NSCLC).